The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

World Sleep
September 5th – 10th 2025, Singapore
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Sleep-wake disorders
PRESENTATION
Vibrance-1: A Randomized Phase 2 Study Evaluating Safety and Efficacy of the Orexin 2 Receptor Agonist Alixorexton (ALKS 2680) in Patients with Narcolepsy Type 1
AUTHOR(S)

Presented by Giuseppe Plazzi

Embargo date: 09-08-2025 Embargo time: 15:15 +08
Sleep-wake disorders
Sleep-wake disorders
PRESENTATION
Improvement in the Severity of Narcolepsy Symptoms and Fatigue in Patients with Narcolepsy Type 1 Treated with the Orexin 2 Receptor Agonist Alixorexton (ALKS 2680)
AUTHOR(S)

Presented by Yves Dauvilliers

Embargo date: 09-08-2025 Embargo time: 15:15 +08
Sleep-wake disorders
Sleep-wake disorders
PRESENTATION
Improvement in Patient-reported Cognitive Functioning in Patients with Narcolepsy Type 1 Treated with the Orexin 2 Receptor Agonist Alixorexton (ALKS 2680)
AUTHOR(S)

Presented by Giuseppe Plazzi

Embargo date: 09-08-2025 Embargo time: 15:15 +08
Sleep-wake disorders
Sleep-wake disorders
ENCORE POSTER
A Phase 2, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of Alixorexton (ALKS 2680) in Patients With Idiopathic Hypersomnia: Study Design and Methods for Vibrance-3
AUTHOR(S)

David Plante1, Ron Grunstein2, Giuseppe Plazzi3, Kiran Maski4, Jandira Ramos5, Yangchun Du5, Alexandra Lovett5, Marcus Yountz5, Bhaskar Rege5

Embargo date: 09-09-2025 Embargo time: 16:45 +08
Sleep-wake disorders